“Drug” Companies are Missing Their Moment to Write a New Narrative
John G. Singer examines how the ongoing coronavirus pandemic may create a new dichotomy for global healthcare – and why pharma companies still wedded to the market models of the…
Creative Biolabs provides custom services and products that cover the full scope of biomedical needs of early drug discovery and drug development.
Creative Biolabs is specialized in providing custom antibody services and products that cover the full scope of biomedical needs of early drug discovery and drug development. As a trusted provider of the most cost-effective outsourcing solutions, Creative Biolabs has been working for a large number of satisfied clients from biotechnology and pharmaceutical companies as well as government and academic research laboratories all over the world.
Contact
John G. Singer examines how the ongoing coronavirus pandemic may create a new dichotomy for global healthcare – and why pharma companies still wedded to the market models of the…
AAM Interim President Jeff Francer outlines the vital role that biosimilar and generics firms will play in filling supply chain gaps during the ongoing coronavirus pandemic. Like the rest…
Artificial intelligence (AI) is increasingly being utilised in the drug discovery process, with the latest breakthrough being the development of an antibiotic that is powerful enough to combat resistant bacteria…
A recent IQVIA report highlights the increasing importance of Indian firms to the USA’s burgeoning generic pharmaceuticals market. Now accounting for over 90 percent of all prescriptions dispensed in…
Over the past few years, innovative Swiss giant Roche has combined its position as the world’s number 1 biotech company and its strength in in vitro diagnostics to brand itself…
Barbara Lopez Kunz, CEO of the Drug Information Association (DIA) in the USA, outlines the association’s four key areas of focus – regulatory science, patient engagement, translational science, and value…
Jonathan Kimball of the Association for Accessible Medicines (AAM) in the USA outlines why the signing of the US-Mexico-Canada Agreement (USMCA) in January 2020 may mark a turning point for…
In an exclusive interview, Janet Woodcock, head of the Center for Drug Evaluation and Research (CDER) at the US Food & Drug Administration (FDA) outlines how the world’s gold-standard agency…
The 2019 Wuhan coronavirus outbreak has seen a surge in demand for protective masks as publics across the world seek to protect themselves from infection. Manufacturers of the masks have…
In 2019, several drug companies testified to the US Senate Finance Committee on medicine price hikes with a narrative of discounts given to health insurance companies and pharmacists, but not…
Takeda’s Jessica S. Scott examines the steps already being taken to bring greater patient engagement to drug development and the regulatory decision-making process in the USA; as well as what…
The Association for Accessible Medicines’ Chip Davis outlines the ways in which the US Medicare programme needs updating in order to promote generic and biosimilar competition and therefore increase patient…
See our Cookie Privacy Policy Here
